Neuropsychological assessments are essential tools for the screening and diagnosis of patients with cognitive impairments. Cultural background differences significantly affect cognitive test performance. For China, which is rapidly aging, a culturally adaptive picture naming test is urgently needed.
Objective
This study aims to develop a Chinese naming test (CNT) adapted to the cultural background of Chinese people and to explore its correlation with Alzheimer's disease (AD) biomarkers.
Methods
A total of 1459 participants were recruited, including 744 with normal cognition (NC), 492 with mild cognitive impairment (MCI), and 223 with dementia. All participants underwent a comprehensive neuropsychological assessment. The diagnostic capability of CNT was determined using Receiver Operating Characteristic curves. Part of participants underwent amyloid-β (Aβ) PET scans, tau-PET scans, and MRI scans. The relationships between CNT scores and Aβ and tau deposition, as well as brain structural changes, were analyzed.
Results
The diagnostic capability of CNT for MCI showed a sensitivity of 68.7%, specificity of 75.6%, and AUC of 0.81; for dementia, the sensitivity was 72.7%, specificity was 89.5%, and AUC was 0.89. The correlation coefficient between CNT scores and brain Aβ burden was −0.11 (p = 0.024). CNT scores correlated with tau burden in different Braak stages (p < 0.05). The correlation coefficient between CNT scores and hippocampus atrophy was −0.15 (p = 0.003).
Conclusions
The CNT has good diagnostic performance in detecting MCI and dementia in Chinese population. There is a correlation between CNT scores and AD imaging markers, indicating that the CNT might has potential value in predicting cognitive changes and disease progression.
PrinceMBryceRAlbaneseE, et al.The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement2013; 9: 63–75.e2.
2.
PetersenRC. Mild cognitive impairment as a diagnostic entity. J Intern Med2004; 256: 183–194.
3.
JiaLDuYChuL, et al.Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. Lancet Public Health2020; 5: e661–e671.
4.
BezdicekORosickáAMManaJ, et al.The 30-item and 15-item Boston naming test Czech version: item response analysis and normative values for healthy older adults. J Clin Exp Neuropsychol2021; 43: 890–905.
5.
XiangCAiWZhangY, et al.Language dysfunction correlates with cognitive impairments in older adults without dementia mediated by amyloid pathology. Front Neurol2023; 14: 1051382.
6.
BartosADiondetS. Sensitive written hedgehog PICture Naming and Immediate Recall (PICNIR) as a valid and brief test of semantic and short-term episodic memory for very mild cognitive impairment. J Alzheimers Dis2024; 102: 396–410.
7.
LiYQiaoYWangF, et al.Culture effects on the Chinese version Boston Naming Test performance and the normative data in the native Chinese-speaking elders in mainland China. Front Neurol2022; 13: 866261.
8.
RosselliMUribeIVAhneE, et al.Culture, ethnicity, and level of education in Alzheimer’s disease. Neurotherapeutics2022; 19: 26–54.
9.
JørgensenKJohannsenPVogelA. A Danish adaptation of the Boston Naming Test: preliminary norms for older adults and validity in mild Alzheimer’s disease. Clin Neuropsychol2017; 31: 72–87.
10.
FernándezALFulbrightRL. Construct and concurrent validity of the Spanish adaptation of the Boston Naming Test. Appl Neuropsychol Adult2015; 22: 355–362.
11.
ChenT-BLinC-YLinK-N, et al.Culture qualitatively but not quantitatively influences performance in the Boston naming test in a Chinese-speaking population. Dement Geriatr Cogn Dis Extra2014; 4: 86–94.
12.
HowiesonD. Current limitations of neuropsychological tests and assessment procedures. Clin Neuropsychol2019; 33: 200–208.
13.
TatsutaNNakaiKSuzukiK, et al.Normative study of the Boston naming test in 7-year-old Japanese children. Nihon Eiseigaku Zasshi2013; 68: 189–196.
14.
BasuraHAMudarrisMAlmubarakFB, et al.Feasibility study of the Boston Naming Test for the Arab population. Cureus2024; 16: e52351.
15.
PaplikarAVargheseFAlladiS, et al.Picture-naming test for a linguistically diverse population with cognitive impairment and dementia. Int J Lang Commun Disord2022; 57: 881–894.
16.
CuiLZhangZGuoY, et al.Category switching test: a brief amyloid-β-sensitive assessment tool for mild cognitive impairment. Assessment2024; 31: 543–556.
17.
YunGKimHJKimH-G, et al.Association between plasma amyloid-β and neuropsychological performance in patients with cognitive decline. Front Aging Neurosci2021; 13: 736937.
18.
PiniLPievaniMBocchettaM, et al.Brain atrophy in Alzheimer’s disease and aging. Ageing Res Rev2016; 30: 25–48.
19.
DevanandDPPradhabanGLiuX, et al.Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology2007; 68: 828–836.
20.
LuoJMaYAgboolaFJ, et al.Longitudinal relationships of white matter hyperintensities and Alzheimer disease biomarkers across the adult life span. Neurology2023; 101: e164–e177.
21.
CuiLHuangLPanF-F, et al.Chinese Preclinical Alzheimer’s Disease Study (C-PAS): design and challenge from PET acceptance. J Prev Alzheimers Dis2023; 10: 571–580.
22.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement2011; 7: 263–269.
23.
BraakHBraakE. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol1991; 82: 239–259.
24.
FujiiDKasedaETHanedaA, et al.Sociodemographic, cultural, linguistic, and test selection considerations for clinical neuropsychological assessment with Japanese and Japanese-American patients in the United States. Clin Neuropsychol2023; 37: 866–895.
25.
FernandezAL. Modern neuropsychological tests for a diversity of cultural contexts. Clin Neuropsychol2019; 33: 438–445.
26.
NielsenTR. Cognitive assessment in culturally, linguistically, and educationally diverse older populations in Europe. Am J Alzheimers Dis Other Demen2022; 37: 15333175221117006.
27.
Delgado-ÁlvarezADelgado-AlonsoCValles-SalgadoM, et al.Normative data in cross-cultural neuropsychological instruments in Spaniards and Colombians living in Spain. J Alzheimers Dis2023; 96: 1231–1241.
28.
LeeSJRitchieCSYaffeK, et al.A clinical index to predict progression from mild cognitive impairment to dementia due to Alzheimer’s disease. PLoS One2014; 9: e113535.
29.
PereiraTLemosLCardosoS, et al.Predicting progression of mild cognitive impairment to dementia using neuropsychological data: a supervised learning approach using time windows. BMC Med Inform Decis Mak2017; 17: 110.
30.
KatsumataYMathewsMAbnerEL, et al.Assessing the discriminant ability, reliability, and comparability of multiple short forms of the Boston Naming Test in an Alzheimer’s disease center cohort. Dement Geriatr Cogn Disord2015; 39: 215–227.
31.
AniwattanapongDTangwongchaiSSupasitthumrongT, et al.Validation of the Thai version of the short Boston Naming Test (T-BNT) in patients with Alzheimer’s dementia and mild cognitive impairment: clinical and biomarker correlates. Aging Ment Health2019; 23: 840–850.
32.
LiampasIFoliaVMorfakidouR, et al.Language differences among individuals with normal cognition, amnestic and non-amnestic MCI, and Alzheimer’s disease. Arch Clin Neuropsychol2023; 38: 525–536.
33.
BaylesKATomoedaCK. Confrontation naming impairment in dementia. Brain Lang1983; 19: 98–114.
34.
BellevilleSFouquetCHudonC, et al.Neuropsychological measures that predict progression from mild cognitive impairment to Alzheimer’s type dementia in older adults: a systematic review and meta-analysis. Neuropsychol Rev2017; 27: 328–353.
35.
BunkerLDWalkerAMeierE, et al.Hyperintense vessels on imaging account for neurological function independent of lesion volume in acute ischemic stroke. Neuroimage Clin2022; 34: 102991.
36.
KimB-SLeeD-WBaeJ-N, et al.Effects of education on differential item functioning on the 15-item modified Korean Version of the Boston Naming Test. Psychiatry Investig2017; 14: 126–135.
37.
OssenkoppeleRSmithRMattsson-CarlgrenN, et al.Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol2021; 78: 961–971.
38.
JohnsonKASchultzABetenskyRA, et al.Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol2016; 79: 110–119.
39.
BejaninASchonhautDRLa JoieR, et al.Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease. Brain2017; 140: 3286–3300.
40.
OssenkoppeleRSmithROhlssonT, et al.Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. Neurology2019; 92: e601–e612.
41.
WeissbergerGHSalmonDPBondiMW, et al.Which neuropsychological tests predict progression to Alzheimer’s disease in Hispanics?Neuropsychology2013; 27: 343–355.
42.
JacobsDMSanoMDooneiefG, et al.Neuropsychological detection and characterization of preclinical Alzheimer’s disease. Neurology1995; 45: 957–962.
43.
GollanTHGarciaDLStasenkoA, et al.The MINT Sprint 2.0: a picture naming test for detection of naming impairments in Alzheimer’s disease and in preclinical AD. Alzheimers Dement2024; 20: 112–123.
44.
HahnAKimYJKimHJ, et al.The preclinical amyloid sensitive composite to determine subtle cognitive differences in preclinical Alzheimer’s disease. Sci Rep2020; 10: 13583.
45.
BischofGNRodrigueKMKennedyKM, et al.Amyloid deposition in younger adults is linked to episodic memory performance. Neurology2016; 87: 2562–2566.
46.
PerosaVZanon ZotinMCSchoemakerD, et al.Association between hippocampal volumes and cognition in cerebral amyloid angiopathy. Neurology2024; 102: e207854.
47.
XiaoYLiaoLHuangK, et al.Coupling between hippocampal parenchymal fraction and cortical grey matter atrophy at different stages of cognitive decline. J Alzheimers Dis2023; 93: 791–801.
48.
ChoiM-HKimH-SGimS-Y, et al.Differences in cognitive ability and hippocampal volume between Alzheimer’s disease, amnestic mild cognitive impairment, and healthy control groups, and their correlation. Neurosci Lett2016; 620: 115–120.
